Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function

Inclusion Criteria: * Proven, peripheral arterial disease, Fontain II-III stage, patient submitted to secondary prophylactic thrombocyte aggregation inhibiting treatment * Doppler index \< 0,8 Exclusion Criteria: * Hypersensitivity to the active ingredient or one of the components of the drug * Active pathological bleeding, e.g. gastric ulcer, intracranial bleeding * Pregnancy, breast-feeding * Severe, known hepatic insufficiency * Severe, known renal insufficiency The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.